Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Mole101on Aug 10, 2021 5:08pm
133 Views
Post# 33679988

RE:RE:RE:RE:RE:For those that Sold at 0.26 CAD Today

RE:RE:RE:RE:RE:For those that Sold at 0.26 CAD Today

RC must be on holidays and as he said in Late June, nothing happening  for couple of months .Several weeks back there was a lot of selling on the .23/25 range by the same houses now reposition at the .18/.20 range ( mainly Nestbet and RBC/ Anon).. again do your DD and whatever strategy you have , is your to make/ loose or hold  ...I would just say that personally I'm under 1 million shares but always willing to add up again , at the right price ;)


garygp wrote: With the modest run-up in the stock over the past month on both volume and price, it appears to me they are putting lipstick on the pig, getting it ready for another financing.

Couple this with Elliot not having left yet, it seems like the perfect storm.  Afterall, he is the leader and Father of dilution and shareholder inequity.

Oh how I hope I am wrong.  Hope the Boston group (FEG) sees through the stupidity and puts a lid on it before it grows.

G.

 

<< Previous
Bullboard Posts
Next >>